2024-09-06 - Analysis Report
## Eli Lilly and Company (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Company is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, including diabetes treatments, cancer therapies, and autoimmune disease medications.

**Performance Analysis:**

**1.  Performance vs. S&P 500:**

*   **Cumulative Return:** LLY has shown a cumulative return of 559.02% compared to 84.86% for the S&P 500 (VOO). This indicates that LLY has significantly outperformed the market.
*   **Relative Performance:** The current relative performance is 454.42, placing it in the 94.48 percentile of its historical performance range. This suggests that LLY is currently performing exceptionally well compared to its historical performance.

**2.  Recent Price Action:**

*   **Closing Price:** $946.31
*   **5-Day Moving Average:** $950.4
*   **20-Day Moving Average:** $923.73
*   **60-Day Moving Average:** $892.32
    
    The recent price action indicates a short-term upward trend, with the closing price above all moving averages. However, the 5-day moving average is slightly below the current price, which could indicate a potential short-term correction.

**3.  Technical Indicators:**

*   **RSI:** 57.49
*   **PPO:** 0.08
    
    The RSI is currently at 57.49, suggesting that the stock is neither overbought nor oversold. The PPO is at 0.08, indicating that the price momentum is slightly positive.
*   **Delta_Previous_Relative_Divergence:** 17.0 (Positive) - This suggests that the current relative performance is improving, indicating a potential short-term upward trend.
*   **Expected Return:** 26.62% - This represents the potential maximum 5-year return for the current investment, offering a positive outlook.

**4.  Recent Earnings & Outlook:**

| Date        | EPS  | Revenue |
|-------------|------|---------|
| 2024-08-08  | 3.29 | 11.30 B$ |
| 2024-04-30  | 2.49 | 8.77 B$ |
| 2023-11-02  | -0.06 | 9.50 B$ |
| 2023-08-08  | 1.96 | 8.31 B$ |
| 2024-08-08  | 1.96 | 8.31 B$ |

The most recent earnings report shows strong results, with EPS exceeding estimates and revenue reaching 11.30 B$. This indicates that the company is performing well, driven by strong demand for its products.

**5.  Overall Analysis:**

Eli Lilly and Company (LLY) is currently performing well, exceeding market returns and showing positive technical indicators. Recent earnings reports indicate strong performance and a positive outlook for the future. However, it is important to note that the 5-day moving average is slightly below the current price, suggesting a potential for short-term correction.

**6.  Investment Recommendation:**

Given the strong performance, positive technical indicators, and strong earnings reports, LLY could be a suitable investment for long-term investors seeking growth potential. However, investors should closely monitor the stock's price action and technical indicators for potential short-term corrections. It is recommended to conduct thorough due diligence and consult with a financial advisor before making any investment decisions.
